Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by Quantbot Technologies LP

by · The Markets Daily

Quantbot Technologies LP trimmed its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 43.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 151,520 shares of the company’s stock after selling 116,756 shares during the period. Quantbot Technologies LP’s holdings in Amneal Pharmaceuticals were worth $1,517,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at about $31,000. Inceptionr LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter worth approximately $115,000. State of Tennessee Department of Treasury purchased a new position in Amneal Pharmaceuticals during the 2nd quarter worth approximately $133,000. Truist Financial Corp purchased a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $137,000. Finally, Rafferty Asset Management LLC lifted its stake in Amneal Pharmaceuticals by 22.0% during the 2nd quarter. Rafferty Asset Management LLC now owns 16,984 shares of the company’s stock valued at $137,000 after acquiring an additional 3,066 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock opened at $13.26 on Friday. The firm has a 50-day simple moving average of $13.78 and a two-hundred day simple moving average of $11.84. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $15.42. The company has a market cap of $4.17 billion, a P/E ratio of 57.65 and a beta of 1.35.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Barclays initiated coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Truist Financial upped their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $14.20.

Get Our Latest Analysis on AMRX

Amneal Pharmaceuticals Profile

(Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Read More